Moveo is an Italian innovative startup producing ExoBand, the first self-powered, lightweight soft exoskeleton/exosuit: based on an elastomer material, it stores the energy generated by hip extensor muscles during walking and uses it to assist motion for patients with walking difficulties, enabling them to walk further, faster and more comfortably.

ExoBand can support physical therapy treatments in medical conditions derived from degenerative diseases (Multiple Sclerosis or Parkinson's disease above all), aging or injured patients. It enhances mobility and allows remote rehabilitation and physiotherapy, with consequent benefits for health, cost savings and improved quality of life. Results of tests carried out confirmed that ExoBand strongly reduces the need for exertion by the user for walking and with a few weeks of training, and patients can increase the distance walked by up to 50%. Prolonging the active life of PD, post-stroke and MS patients has a major impact on their quality of life, and the technology is also very timely to tackle the socio-economic challenge of an aging population with a significant proportion having mobility difficulties.

ExoBand is protected by 2 patents, has obtained the CE mark, is certified as a Class 1 medical device, and is approved for reimbursement in Italy.In early 2022 it was classified as a "class I exempt" by the FDA, which will favor the market entry phase in the US planned for 2023. The company attracted the interest of KOL (neurologists, physiotherapists, rehabilitation centres) and has gained considerable acceptance from end users, translated into direct sales: ExoBand devices are currently sold in +50 medical stores in Italy and are used in +20 medical centers in Italy. Additionally, Moveo has started commercialization in European countries such as the UK, Norway, France, Germany and Ireland.